On November 4, 2026, Alnylam Pharmaceuticals announced the departure of Tolga Tanguler from his role as Executive Vice President, Chief Commercialization Officer, effective December 2026. A written agreement regarding the terms of his departure is expected to be finalized before his separation date. The company continues to advance its strategic initiatives while managing executive transitions.
Who to call at Alnylam Pharmaceuticals, and when
A new leader at Alnylam Pharmaceuticals brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Alnylam Pharmaceuticals raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Alnylam Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alnylam Pharmaceuticals. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Alnylam Pharmaceuticals
Location
Cambridge, Massachusetts, United States
About
Alnylam Pharmaceuticals, Inc. is a leading RNAi therapeutics company focused on developing novel medicines to treat genetically defined diseases. The company is committed to bringing innovative treatments to patients suffering from serious conditions. Their investigational product vutrisiran is designed to treat transthyretin amyloidosis with cardiomyopathy, aiming to improve patient outcomes through advanced therapeutic approaches.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alnylam Pharmaceuticals changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma